Farxiga demonstrates reduced progression of kidney disease in type-2 diabetes patients: ADA meeting

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has released new date from a pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, showing that Farxiga (dapagliflozin) reduced the progression of kidney disease or renal death in patients with type-2 diabetes (T2D).

These data, presented yesterday at the American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, USA,showed a 47% reduction with Farxiga in the relative risk of the composite renal-specific outcome of kidney function decline (sustained ≥40% decrease in estimated glomerular filtration rate [eGFR] to <60 mL/min/1.73m2), end-stage renal disease (ESRD), or renal death (excluding cardiovascular death) compared to placebo (1.5% versus 2.8%; HR 0.53 [95% CI 0.43-0.66]).1

Additionally, Farxiga reduced the relative risk of a cardio-renal composite of kidney function decline, ESRD, or renal or cardiovascular (CV) death by 24% compared to placebo (4.3% vs. 5.6%; HR 0.76 [95% CI 0.67-0.87]).